Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06669117 · ClinicalTrials.gov registry record · Phase 1
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
A Phase 1 study of Solid Tumor and MET Alteration, sponsored by Pierre Fabre Medicament.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
- 19
- Study locations
NCT06669117 is a Phase 1 study of Solid Tumor and MET Alteration that is actively recruiting participants, run by Pierre Fabre Medicament. The registered enrollment target is 140 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (37% lower). The trial reports 19 study locations across 4 states.
The verdict
NCT06669117, a Phase 1 study of Solid Tumor and MET Alteration, is actively recruiting participants, sponsored by Pierre Fabre Medicament.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
- 19
- Study locations
Study Summary
The goal of this clinical trial is to investigate the safety, the activity of VERT-002 (PFL-002), and the optimal safe dose to be used, in participants with solid tumors including non-small cell lung cancer.
Conditions Studied
Interventions
- DRUG VERT-002
Study Locations (19)
Other
- Institut Jules Bordet - Anderlecht
- APHP de Marseille - Hôpital Nord - Marseille
- Institut de Cancerologie de Ouest (ICO) - Saint-Herblain - Saint-Herblain
- Institut Universitaire du Cancer de Toulouse - Oncopole - Toulouse
- Gustave Roussy - Villejuif
- Universitaet zu Koeln - Centrum fuer Integrierte Onkologie (CIO) - Cologne
- Universitätsklinikum Carl Gustav Carus Dresden - Dresden
- Azienda Ospedaliero - Universitaria San Luigi Gonzaga - Orbassano
- Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis - Amsterdam
- Yonsei University College of Medicine - Seoul
- Asan Medical Center (AMC) - Seoul
- Hospital Universitario 12 de Octubre - Madrid
- Hospital Universitario La Paz - Madrid
- National Taiwan University Hospital - Taipei
- Taipei Medical University Hospital - Taipei
- Taipei Veterans General Hospital - Taipei
District of Columbia
- Georgetown Lombardi Comprehensive Cancer Center - Washington D.C.
Ohio
- Gabrail Cancer Research Center - Canton
Tennessee
- Sarah Cannon Research Institute Oncology Partners - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2024-10-22 |
| Est. Completion | 2032-10-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06669117
The ClinicalTrials.gov registry entry for NCT06669117 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (37% lower). The listed sponsor is Pierre Fabre Medicament, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which VERT-002 is the first listed.
NCT06669117 reports 19 study locations spanning 4 distinct geographic areas - top geographies include Other, District of Columbia, Ohio.
Frequently Asked Questions
What is clinical trial NCT06669117 about?
NCT06669117 is a clinical study titled "FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations". The goal of this clinical trial is to investigate the safety, the activity of VERT-002 (PFL-002), and the optimal safe dose to be used, in participants with solid tumors including non-small cell lung cancer.
What is the current status of trial NCT06669117?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2024-10-22. Estimated completion is 2032-10-01.
What conditions does trial NCT06669117 study?
This clinical trial studies the following conditions: Solid Tumor, MET Alteration.
What interventions are being tested in trial NCT06669117?
The interventions under investigation include: VERT-002 (DRUG).
Who is sponsoring clinical trial NCT06669117?
This trial is sponsored by Pierre Fabre Medicament, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06669117 being conducted?
This trial has 19 study locations across District of Columbia, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.